Josh Kopelman

AI is closing the investor “trust gap” in healthtech. One of the more interesting ideas in Bessemer Venture Partners’ State of Health AI 2026 is that investors are increasingly looking toward healthtech, not because the story got better, but because the fundamentals did. A few points from the report are worth highlighting: -> Trust gap: after the last healthtech cycle, many investors became more cautious. Looking at public markets, new healthtech stocks still trade at a 10–20% discount to cloud peers despite 2x revenue growth and cash flow margins. But the gap is closing. -> Velocity is different this cycle: healthcare AI companies are reaching $100M ARR faster than prior healthcare software cohorts. -> Clinical AI is maturing the “right” way as clinicians-in-the-loop products, built for today’s reality, are where AI is delivering real value in healthcare. The next 12–24 months will be an important window for healthcare technology founders. The upside is massive, translating technology momentum into measurable efficiency gains and better patient outcomes. Link to report in comments.

15

3 Comments

What do creative technologists build? At Baukunst, we’ve spent the last few years answering that question in real time. We are a collective of builders — operators, designers, engineers, and investors — committed to advancing the art of building at the frontiers of technology and design. We lead pre-seed rounds with conviction, often as the first institutional capital a founder takes, and we invest deeply in the messy, magical early days of company creation. This deck is the portfolio behind that philosophy, or rather that portfolio that has grown up out of it. We have chosen to champion these companies, and they chosen to co-create with us. These are companies built by creative technologists, founders who think in systems, design for real people, and push beyond the familiar. 

55

6 Comments

New founder Q&A on our site! Love what Ralph Betesh is building at Coverdash! Anyone who has insured a small business knows the drill: a phone call, a PDF, and a week of waiting. Coverdash turned that into a few clicks — and then put it inside the platforms small businesses already use, so coverage gets offered at the moment of need instead of chased down later. That last part is what got our attention. Insurance is a distribution business more than a product business, and owning the point of sale is a durable advantage in a market this fragmented. Link below — worth a few minutes.

8

2 Comments

I've looked at a lot of YC batches. The bio and health lineup in P26 is STACKED. https://lnkd.in/gQKxpe9t Adialante - Compact, mobile whole-body MRI to make cancer screening accessible at hundreds per scan FinalDose - A programmable drug that reads DNA inside the cell and destroys it if it's diseased, starting with previously undruggable cancer targets Voquill (YC P26) - An AI coworker for pathologists that learns your reporting style and produces sign-out ready reports in real time Clara - An AI primary care doctor with a licensed clinician reviewing every medical decision Lumius (YC P26) - Affordable, real-time 3D ultrasound, starting with vascular access

112

7 Comments

We are excited to announce that MFV Partners and Harper Court Ventures have invested in CavilinQ's $8.8M seed round to build the interconnect layer for scalable quantum computing. I first met Shankar G Menon over a year ago, before CavilinQ even existed as a company. Since then, I've spent time with him in the labs, watching the idea take shape and learning about the technical approach. What stands out is Shankar's clarity of vision, his conviction in the technology, his maturity as a founder, and his willingness to learn and adapt as the company has come together. MFV's quantum journey started with our investment in PsiQuantum at the core of quantum computing. Since then, we've been looking for opportunities in the higher layers of the stack needed to make quantum computing practical at scale. CavilinQ sits squarely in that thesis — they are building cavity-enhanced photonic links that connect isolated quantum processors into modular, high-performance clusters. This is the networking infrastructure the quantum ecosystem will need as processors continue to advance. The technology builds on foundational research by Prof. Misha Lukin at Harvard and Prof. Hannes Bernien at UChicago, two of the leading researchers in light-matter interfaces. We're pleased to be working alongside Misha and the scientific team as CavilinQ moves to commercialize their technology. We're also glad to partner with QVT, Safar Partners (a co-investor with us in Agility Robotics), and Serendipity Capital. Congratulations to Shankar and the CavilinQ team. We look forward to being part of their exciting journey!

55

2 Comments

Seed-stage fundraising requires differentiation. Grind Ventures found it at the intersection of three underserved markets Technology transfer from universities creates early-stage opportunities that most VCs miss. Defense and federal marketplace applications provide revenue visibility. Critical infrastructure sectors offer commercial scale. Focused Thesis - Dual-use technologies serving defense and 16 critical infrastructure sectors Technology Transfer - University research teams1-5 years old at $1-3M valuations Revenue Clarity - Federal marketplace provides structured procurement pathways Commercial Scale - Critical infrastructure sectors offer massive addressable markets   Geographic Focus - US-based companies with clear domestic advantages Stage Discipline - Seed investments with defined entry points and milestones The market rewards problem-obsessed founders with healthy margins and cash flow visibility. Dual-use technology delivers both. Which of these thesis elements resonates most with your investment approach? #VC #GrindVentures #ThoughtLeadership

19

6 Comments